Journal of Oncology Pharmacy Practice

Article	Citations
Safety of intramuscular tixagevimab-cilgavimab (Evusheld®) administration in patients at risk of iatrogenic haematoma due to haematological disorders	26
Predictors of community pharmacists’ readiness to manage the effective and safe use of oral anticancer medicines in a developing setting	26
Nivolumab-induced sensory ganglionopathy	25
Investigation of 5-fluorouracil cardiotoxicity in combinational therapy: Influence of risk factors and demographics in a Pakistani population	22
Perspectives toward biosimilars among oncologists: A Malaysian survey	18
The physical exam’s role in determining dose-limiting toxicity prior to immunochemotherapy administration in lymphoma	14
Descriptive study of clinical pharmacist interventions in adult hospice and palliative care at a comprehensive oncology center in Jordan	13
Acceptance of coronavirus disease 2019 vaccination by cancer patients in Cyprus: A cross-sectional study	13
Polypharmacy and drug-drug interactions in metastatic breast cancer patients receiving cyclin-dependent kinase (CDK) 4/6 inhibitors	12
Multiple cardiotoxicities during osimertinib therapy	12
Impact of low- and high-risk operators handling irinotecan on the blood contamination of health care workers in oncology day care units	11
Development and use of an innovative Gap Finding Tool to create a Pharmaceutical Care Model within a paediatric oncology setting	11
Impact of a Pharmacist-Led Hypertension Management Program for Oral Chemotherapy in a Specialty Pharmacy Setting	11
Vincristine induced fever in a child with embryonal rhadbomyosarcoma	11
Residual chemotherapy drugs after flushing infusion lines	11
Experiences of the combined use of Favipiravir in patients using Lorlatinib and Brigatinib	11
Knowledge and practices about safe handling regarding the risk of exposure to antineoplastic drugs for caregivers in compounding units and in operating rooms performing HIPEC/PIPAC	10
Evaluating the efficacy of a premedication regimen including high-dose cetirizine in reduction of hypersensitivity reactions to paclitaxel: A retrospective cohort study	10
The regulatory saga of fedratinib	10
Corrigendum to “Anti-cancer medicine shortages in an oncology tertiary hospital of Pakistan: A five-year retrospective study”	9
Providing medication alternatives during intranasal desmopressin recall	9
Nivolumab-induced immune-related neutropenia in a renal cell carcinoma patient	9
Successful Treatment of a 92-Year-Old Classic Kaposi's Sarcoma Man With Ultra-Low Dose Oral Etoposide	8
Toxicity analysis of busulfan pharmacokinetic therapeutic dose monitoring	8
Horse antithymocyte globulin test doses and infusion reactions in adults with aplastic anemia: A multicenter retrospective experience	8

Contribution of an anticancer drug compounding robot in reducing the risks of manual preparation in a hospital pharmacy unit specialized in oncology	8
Preparations of exploration of immediate hypersensitivity to antineoplastic agents: An oncology pharmacy perspective	8
Retrospective evaluation of adjuvant capecitabine dosing patterns in triple negative breast cancer	8
Potential added value of combined DPYD/DPD genotyping and phenotyping to prevent severe toxicity in patients with a DPYD variant and decreased dihydropyrimidine dehydrogenase enzyme activity	8
Central nervous system neurotoxicity associated with nelarabine in T-cell acute lymphoblastic leukemia	8
Influence of the implementation of a multidisciplinary consultation program on adherence to the first ever course of oral antineoplastic treatment in patients with cancer	8
Evaluation of antibiotic appropriateness at an outpatient oncology centre	8
Pharmacotherapy and psychological support: Integrating pharmacists into comprehensive cancer care – a literature review	8
Liver toxicity with ribociclib in a patient with metastatic hormone receptor positive postmenopausal breast cancer	8
Treatment with doxorubicin-based protocol in cardiac involvement diffuse large B-cell lymphoma: A case report	8
Global changes to the chemotherapy service during the covid-19 pandemic	7
Life-threatening altered mental status secondary to memantine in an adolescent undergoing cranial radiotherapy for medulloblastoma	7
Abstracts	7
Atezolizumab-induced cerebellar ataxia in a patient with metastatic small cell lung cancer: A case report and literature review	7
Corrigendum to Lonsurf (trifluridine/tipiracil): assessing the impact of dose related toxicities and progression free survival in (refractory) metastatic colorectal cancer	7
A study to assess the impact of pharmaceutical care services to cancer patients in a tertiary care hospital	7
Determination of drug–drug interaction in breast cancer patients receiving doxorubicin and cyclophosphamide regimen	7
Hydroxyurea- a cost effective treatment in developing countries for Atypical Chronic Myeloid Leukemia (aCML): Case Report of Two Patients	7
A successful initiation of treatment of Hodgkin's lymphoma with adriamycin-bleomycin-vinblastine-dacarbazine dose reduction in a patient with fulminant hepatic failure and co-infection with human immu	7
Efficacy and safety of topical 5-fluorouracil in conjunctival intraepithelial neoplasia refractory to interferon alpha-2b	7
Health-related quality of life of women with breast cancer being treated with hormone therapy: A scoping review	7
Determinants of clinic absenteeism in a chemotherapy service of a cancer center located at Rio de Janeiro, Brazil	7
MTHFR 677T-1298C haplotype in acute lymphoblastic leukemia: Impact on methotrexate therapy	7
Assessment of patients’ knowledge of their treatment with capecitabine at the National Institute of Oncology in Rabat	7
Investigation of the frequency of bortezomib neuropathy in patients with multiple myeloma diagnosis with normal and abnormal genetic characteristics	6
Cellular therapy site-preparedness: Inpatient pharmacy implementation at a large academic medical center	6
Severe acute radiation dermatitis after palbociclib therapy in the setting of palliative radiotherapy	6
Initial real-world experience with ribociclib in advanced breast cancer	6
Oncology boot camp: A preparatory curriculum for advanced pharmacy practice experience students	6
Vaccine response after pneumococcal vaccination in allogeneic hematopoietic stem cell transplant recipients	6
Characterization of education, technical practices and attitudes of Portuguese pharmacy technicians towards manipulation of cytotoxic drugs	6
Concomitant use of calcitonin gene-related peptide (CGRP) antagonists with azole antifungals in patients with hematological malignancies	6
Invasive Aspergillosis of the Spleen in the setting of Ibrutinib use	6
Evaluation of contraception methods in chronic myeloid leukemia patients: A Turkish multicenter study	6
Managing medications for patients with cancer and chronic conditions: It's time for collaboration between primary care and oncology pharmacists	6
Evaluation of a primary antifungal prophylaxis protocol for preventing invasive mold infections after allogeneic hematopoietic stem cell transplantation	6
Impact of initiating oral anticancer agents for leukemia on adherence to medications for multiple chronic conditions	6
Posaconazole versus voriconazole as antifungal prophylaxis for invasive fungal diseases in patients with hematological malignancies	6
Assessment of molecular response to tyrosine kinase inhibitors in Tunisian Patients with Chronic Myeloid Leukemia	6
Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy	6
Corrigendum to Gemcitabine-induced dilated-cardiomyopathy in patient with platinum-refractory ovarian-cancer: A case report and literature review	6
Comparing the effectiveness of biosimilar filgrastim (Nivestim®) versus original filgrastim (Neupogen®) for stem cell mobilization in adult and pediatric healthy donors	6
Severe neutropenia probably caused by enzalutamide and abiraterone in a prostate cancer patient	6
Investigating Potential Drug-Drug Interactions in Pediatric and Adolescent Patients Receiving Chemotherapy	6
Phosphatidylinositol 3-kinase signaling inhibitors for treatment of multiple myeloma: From small molecules to microRNAs	6
Safety and efficacy of Vitamin C, Vitamin E, and selenium supplementation in the oncology setting: A systematic review	6
Trastuzumab-induced optic neuritis: “blindness” side effect	6
Analysis of chemical contamination by hazardous drugs with BD HD Check® system in a tertiary hospital	6
Successful use of split-dose intravenous daratumumab in a multiple myeloma patient after a first-dose life-threatening infusion-related reaction	6
Evaluation of the quality of life of adult patients admitted to the bone marrow transplantation unit	6

Evaluation of real-world versus clinical trial outcomes of tyrosine kinase inhibitor therapy for chronic myeloid leukemia	6
Outcome of antiemetic prophylaxis among pediatric cancer patients receiving moderate to highly emetogenic chemotherapy at pediatric hemato-oncology ward of Tikur Anbessa specialized hospital: A pr	6
Hypercalcemia associated with interaction between all trans retinoic acid and fluconazole in an acute promyelocytic leukemia and acquired hypoparathyroidism case	6
Life-threatening sustained hypocalcemia following Denosumab use in metastatic prostate cancer	6
Re-use of erlotinib in a patient using osimertinib after erlotinib, case report	5
Rituximab-induced severe acute thrombocytopenia in a patient with splenic marginal zone lymphoma	5
The effect of examining somatic alterations with NGS in patients with solid tumors, on patient management: A single-center experience in Turkey	5
Clinical and Economic Impact of Pharmacists’ Intervention on Care of Pediatric Hematology and Oncology Patients	5
A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer	5
Oral lichenoid drug eruption due to osimertinib for lung cancer	5
Pharmacists’ practices and views regarding management of sexual health in patients with cancer	5
Pharmacological profile and potential drug interactions in ovarian cancer hospitalized patients	5
Management and health-related quality of life among patients with prostate cancer in a Kenyan tertiary health facility	5
Novel genetic structures associated with adverse response to chemotherapy in breast cancer	5
Corrigendum to A review on radiation induced nausea and vomiting: “Current management strategies and prominence of radio sensitizers”	5
Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma	5
Preventing drug vial wastage and reducing expenditure associated with injectable cancer drugs: International oncology pharmacy survey	5
Administration of ciprofloxacin through a nasogastric tube in pediatric oncology and stem cell transplantation patients	5
Brigatinib is a cost-effective treatment in first-line anaplastic lymphoma kinase mutation-positive (ALK + ) advanced non-small cell lung cancer (NSCLC) with brain metastases	5
Post COVID availability of oncology drugs – Is this the new normal on both sides of the Atlantic?	5
eviQ Education releases free pharmacy anti-cancer drug course for cancer pharmacists	5
Pneumonitis associated with Trastuzumab emtansine in a patient with metastatic breast cancer	5
Nivolumab-induced pneumonitis and cardiopathy in a patient with relapsed Hodgkin's lymphoma	5
Patterns of prescription opioid use and opioid-related harms among adult patients with hematologic malignancies	5
Optimizing medication therapy in elderly patients: The impact of medication review using STOPP and START criteria version 2	5
Evaluation of awareness about importance of high fever in leukemia and lymphoma patients receiving chemotherapy among healthcare professionals working in pharmacies other than hospital pharmacies: A s	5
Dosing of 7 + 3 induction chemotherapy in a patient with acute myeloid leukemia (AML) and morbid obesity	5
Mercaptopurine induced myelosuppression in a child with a NUDT15 rs116855232 homozygous variant	5
Daratumumab Monotherapy for Heavily Pre-treated and Refractory Myeloma: Results from a UK Multicentre Real World Cohort	5
Pneumonitis associated with bortezomib in a patient with multiple myeloma	5
Non hemorrhagic pericardial effusion from ibrutinib İn a patient without comorbidities	5
Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis	5
Tyrosine kinase inhibitor-induced immune hemolytic anemia; three different drugs in three separate cases	5
Pro-adherence complementary audiovisual educational intervention model for chronic myeloid leukemia patients treated with imatinib mesylate	5
In vitro compatibility of admixture solutions of 5-fluorouracil and khapzory (disodium levofolinate) in a single infusion bag	5
Immunosuppressant adherence in adult outpatient hematopoietic cell transplant recipients	4
Biotin-induced thyroid stimulating hormone aberrations in the setting of immunotherapy	4
Incidence of immune-related adverse events in U.S. veterans treated with immune checkpoint inhibitors	4
The clinical and financial impact of remote clinical oncology pharmacist engagement in community-based practices within The US Oncology Network	4
Pro-BNP in the differential diagnosis of dyspnea in patients treated with immune-checkpoint inhibitors: Case Report	4
Abstracts	4
Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers	4
Rationalizing prescription via deprescribing in oncology practice	4
Predictive and prognostic biomarkers with therapeutic targets in colorectal cancer: A 2021 update on current development, evidence, and recommendation	4
Factors affecting medication adherence in patients using oral chemotherapy: A descriptive study	4
Myocardial bridge in a patient with castration-resistant metastatic prostate cancer treated with enzalutamide	4
Nearly complete hair re-pigmentation in an older patient treated with hydroxyurea for essential thrombocytosis	4
Workflow evaluation of environmental contamination with hazardous drugs during compounding and administration in an UK hospital	4
Vinorelbine-related tetraplegia due to severe peripheral neuropathy	4
Elotuzumab: Empiric analysis of dexamethasone administration schedule	4
CAPhO Conference 2023 Abstract Book	4
Osimertinib induced cardiac failure and QT-prolongation in a patient with advanced pulmonary adenocarcinoma	4
KRAS-targeted therapy in the treatment of non-small cell lung cancer	4
Factors associated with potentially inappropriate medications in elderly with multiple myeloma	4
Desensitization to Brentuximab Vedotin after anaphylaxis in refractory Hodgkin's lymphoma	4
Barriers to opioid use in the Arab world	4
Use of nab-paclitaxel and gemcitabine in pancreatic cancer without granulocyte colony-stimulating factor: A multicenter real-world experience	4
Risk assessment of personnel exposure in a central cytotoxic preparation unit using the FMECA method	4
Liposomal amphotericin for secondary prophylaxis: A systematic review and meta-analysis	4
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey	4
Medication-related problems among patients with cervical cancers at oncology centers of University of Gondar comprehensive specialized hospital: A hospital-based retrospective study	4
Prevalence of cannabidiol (CBD) consumption and cancer patients’ expectations in one oncology day-hospital: A cross-sectional study and questionnaire validation	4
The impact of early versus late tocilizumab administration in patients with cytokine release syndrome secondary to immune effector cell therapy	4
Brigatinib-associated autoimmune hepatitis: A case report	4
Improving palbociclib adherence among women with metastatic breast cancer using a CONnected CUstomized Treatment Platform: A pilot study	4
Management of Nelarabine induced neurotoxicity in a child with T-cell acute lymphoblastic lymphoma	4
Retrospective study evaluating immune-related adverse events in cancer patients treated with pembrolizumab	4
Incidence and management of patients with methotrexate delayed elimination in the clinical practice: A Delphi study	4
Assessing the impact of aprepitant on response to dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP)	4
Pirtobrutinib: A novel non-covalent BTK inhibitor for the treatment of adults with relapsed/refractory mantle cell lymphoma	4
Advanced uterine papillary serous cancer: Could there be a role for newer targeted therapeutic approaches or immune checkpoint inhibitors?	4
Local and systemic side effects of COVID-19 vaccine in Tunisian cancer patients: A prospective single center study	4
Clinical utility of a regional precision medicine molecular tumor board and challenges to implementation	4
A comprehensive evaluation of the safety of ipilimumab, nivolumab and their combination therapy: A systematic review and network meta-analysis	4
Bendamustine-induced nephrogenic diabetes insipidus – A case report	4
A retrospective, real-life analysis of metronomic oral single-agent cyclophosphamide for the treatment of platinum-pretreated advanced ovarian carcinoma in Italy	4
A room of errors simulation to improve pharmacy operators’ knowledge of cytotoxic drug production	4
Temporal effect of imatinib adherence on time to remission in chronic myeloid leukemia patients	4
Midostaurin-Associated acute pancreatitis	4
Patterns and predictors of antidepressant prescribing among adults with cancer and depression in ambulatory care settings in the United States	4

Trend analysis of pharmacist involvement in cancer care in Japan from 2015 to 2020: A nationwide survey study on hospital pharmacy practice	4
Alectinib continuation during COVID 19 ‘antiviral’ treatment: Risk or benefit?	4
Evaluation of cyclin-dependent kinase 4/6 inhibitor-induced serum creatinine elevations in patients with hormone receptor positive breast cancer	4
Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer	4
The impact of medication reconciliation and review in patients using oral chemotherapy	3
Use of two general-purpose scales to assess clinical pharmacy activities in a cell transplantation unit	3
Predictors of lenalidomide maintenance duration after autologous stem cell transplant in patients with multiple myeloma	3
Community Pharmacists’ Knowledge on Cancer and Screening Methods	3
Evaluation of denosumab in adult oncology patients for the prevention of skeletal related events across a large academic health system	3
Game-based learning as training to use a chemotherapy preparation robot	3
Attitude of healthcare professionals toward the use of complementary and alternative medication during anti-cancer therapy	3
Abiraterone acetate-associated QT prolongation and torsades de pointes: Postmarketing cases reported to FDA	3
Vitamin E and levocarnitine as prophylaxis against doxorubicin-induced cardio toxicity in the adult cancer patient: A review	3
Nivolumab treatment in a patient with BRAF mutant advanced melanoma and liver failure with encephalopathy	3
Impact of pharmacist managed oral epidermal growth factor receptor inhibitors	3
Does circle priming improve smart infusion pump and electronic health record interoperability for chemotherapy in a pediatric hematology/oncology setting?	3
Ocular toxicity following carboplatin chemotherapy for neuroendocrine tumour of the bladder	3
Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced or metastatic breast cancer	3
Atezolizumab-associated myositis in a patient with unresectable hepatocellular carcinoma	3
Case report: Proton pump inhibitor drug-related problem in pancreatic cancer patient unmasks pancreatic enzyme insufficiency	3
What patient assessment skills do pharmacist independent prescribers require to prescribe immunomodulators in myeloma?	3
One versus two sets of busulfan therapeutic drug monitoring in myeloablative allogeneic hematopoietic cell transplant	3
A review of sunscreen in the prevention of skin cancer	3
Nivolumab–ipilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment	3
The effect of Bevacizumab treatment on the incidence of hypertension in patients with ovarian cancer: a systematic review and meta-analysis	3
Comparison of intermittent intravenous tacrolimus to continuous tacrolimus in adult allogeneic stem cell transplant recipients	3
Canadian monitoring program of the surface contamination with 11 antineoplastic drugs in 124 centers	3
A two-tool assessment of the quality of life of patients with breast cancer using generic and disease-specific tools in a Nigerian teaching hospital	3
Two different immune related adverse events occured at pancreas after nivolumab in an advanced RCC patient	3
Impact of obesity on doxorubicin pharmacokinetics in women with breast cancer	3
Cyclophosphamide exposure via sweat of patients receiving CHOP therapy	3
Innovative strategies for effective paclitaxel delivery: Recent developments and prospects	3
Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial	3
Redispensing of expensive oral anticancer medicines: A practical application	3
Anticancer medicines in Pakistan: An analysis of essential medicines lists	3
Recurrent arthritis as an unexpected side effect associated with azacitidine in a patient with myelodysplastic syndrome	3
Papilledema and idiopathic intracranial hypertension due to the possible potentiation of ATRA by posaconazole in a case of acute promyelocytic leukemia	3
Assessment of pharmacy students’ knowledge about breast cancer and colon cancer in Northern Cyprus universities	3
Initial assessment of multi-compound antineoplastic drug surface contamination in Argentinean healthcare centers: Insights into occupational exposures in South America	3
The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials	3
Severe Generalized Weakness, Paraplegia following administration of Oxaliplatin in a patient with refractory T-cell non-Hodgkin lymphoma: A case report	3
Recurrent and atypical immune checkpoint inhibitor-induced pneumonitis	3
Advancements in the use of nanopharmaceuticals for cancer treatment	3
Real world comparison of immune-related adverse events with nivolumab-relatlimab versus ipilimumab-nivolumab in patients with advanced cutaneous melanoma	3
A contemporary review of rearranged during transfection-selective inhibitors	3
Management of chimeric antigen receptor T-cell induced cytokine release syndrome: Current and emerging approaches	3
Trousseau’s syndrome in a non-small cell lung cancer patient aggravated by pembrolizumab	3
Comprehensive pharmacological geriatric assessment compared to usual care in an older adult with cancer in the absence of polypharmacy	3
Community pharmacists preparedness and barriers for cancer health promotion in North Cyprus	3
Developing a flowchart to evaluate the use of Closed System Drug-Transfer Devices with monoclonal antibodies: Focus on the clinical trial setting	3
Acute pancreatitis associated with pembrolizumab-induced hypertriglyceridemia	3
Pharmacist interventions in optimising opioid medication therapy in pain management for palliative care patients: A systematic review	3
Response letter to “Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers”	3
Grade 3 cytolysis in a patient with metastatic colorectal cancer consuming a mushroom powder-based alternative therapy	3
Successful desensitization to etoposide in a patient after cardiac arrest	3
Delayed presentation of vincristine extravasation	3
Widespread vitiligo and poliosis following ipilimumab–nivolumab combination therapy	3
Real-world treatment outcomes from a retrospective cohort of patients with acute myeloid leukemia from an urban safety net hospital	3
Perceptions and satisfaction of oncology pharmacy services among cancer patients and healthcare providers at the central zone hospital's oncology section	3
Manual versus automated chemotherapy preparation: A retrospective pharmaco-economic analysis	3
A comparative review of Aphexda and Mozobil for mobilization prior to stem cell collection	3
Drug extravasation with Enfortumab vedotin	3
Azacitidine as a rare cause of reactive arthritis in a patient with acute myeloid leukemia	3
Safety outcomes of rapid- versus standard-infusion rate oxaliplatin	3
Atopy, allergen sensitization and development of hypersensitivity reactions to paclitaxel	3
Developing wipe sampling strategy guidance for assessing environmental contamination of antineoplastic drugs	3
Randomized clinical trials and real life studies: Comparison of baseline characteristics of patients in oral target therapies for renal cell carcinoma	3
CAPhO Conference 2024 Abstract Book	3
Implementation of a medication delivery service for ambulatory oncology infusion patients	3
Incorporation of novel therapies for the management of sickle cell disease: A pharmacist's perspective	3
Evaluation of cancer drug infusion devices prior to the implementation of a compounding robot	3
The experience of cancer patients during the COVID-19 pandemic	3
Adjuvant Capecitabine In Triple Negative Breast Cancer: The Earlier, The Better?	3
Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis	3
Gemcitabine-associated digital necrosis in metastatic breast cancer	3
Late renal toxicity in patient with radioiodine-refractory differentiated thyroid cancer treated with lenvatinib: A case report and literature review	3
Cycle-dependent eosinophilia due to adjuvant nivolumab for malignant melanoma	3
Implementation of pharmaceutical care service to elderly cancer patients in a tertiary care hospital in South India	3
Impact of institutional interventions on the rate of paclitaxel hypersensitivity reactions	3
Gravimetric-based technology-assisted workflow system for injectable anticancer drugs compounding: Design and qualification of an original weighing scale anchored inside an isolator	3
Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers	3
Revitalizing oncology medications access in Saudi Arabia: Current challenges and recommendations by the Saudi Oncology Pharmacy Assembly	3
Withdrawal pain following patients discontinuing Trk inhibitors	3
Effects of consultations and interventions in a pharmacist-led outpatient clinic on duration of treatment and adverse events with osimertinib	3
Drug-related problems in cancer patients: A systematic review	3
Premedication strategy in cetuximab rechallenge after Grade 2 hypersensitivity reactions	3
Enteral tube administration of extemporaneously compounded suspensions of venetoclax according to an institutional medication use process	3
Subacute cutaneous lupus erythematosus following ribociclib therapy for metastatic breast cancer	2
Treatment of BRCA 1 mutated breast cancer with a PARP inhibitor and an Immune Checkpoint Inhibitor	2
Clinical uses and safety concerns of tyrosine kinase inhibitors with a focus on novel drugs: A narrative review	2
Orbital myeloid sarcoma treated with low-dose venetoclax and a potent cytochrome P450 inhibitor	2
Closed-system transfer device use with oncology biologics: A survey of Canadian healthcare practitioners	2
Optimizing intermittent dosing of oral small molecule inhibitors	2
Unexpected pancytopenia: Dasatinib induced aplastic anemia in chronic myeloid leukemia	2
Assessment of polypharmacy, potentially inappropriate medications, and drug-drug interactions in older patients with cancer	2